Coronavirus: US scientists work on vaccine; WHO to determine severity
Scientists at the National Institutes of Health (NIH) in the US have already started working...
Read More...
Focus:
China
-
![Zydus licences anaemia drug to China Medical System]()
Zydus licenses anaemia drug to China Medical System
Pharmaceutical company Zydus Cadila has signed a licensing agreement with China Medical System (CMS) to...
Read More...
-
![]()
New Wuhan coronavirus spreads to Thailand and Japan
On December 31 2019, China alerted the World Health Organization (WHO) about a mysterious outbreak of pneumonia in Wuhan, the…
Read More…
-
![]()
WHO states coronavirus from China could spread, issues warning to hospitals
The World Health Organization (WHO) has announced that China’s new coronavirus could lead to a...
Read More...
-
![]()
New Alzheimer’s drug launches in China amid efficacy doubts
Shanghai Green Valley Pharmaceuticals’ new Alzheimer’s disease drug, Oligomannate, has been conditionally approved in China and became available for purchase…
Read More…
-
![China R&D deals]()
China in 2019: a prime destination for pharma R&D deals
Big pharma’s race for access to China’s pharma market has become bizarre at times; with...
Read More...
-
![]()
China’s Tyvyt beats all top PD-1 inhibitors to the national reimbursement list
Tyvyt is currently being investigated in nine Phase III clinical trials for five different cancer...
Read More...
-
![Lynparza approval]()
AstraZeneca-Merck’s Lynparza approved in China for ovarian cancer
AstraZeneca and Merck (MSD) have received the National Medical Products Administration (NMPA) approval in China...
Read More...
-
![]()
Guangdong’s 10-point plan part of southern Chinese pharma industry ‘growth pole’ campaign
Most Chinese pharma companies are located in the country’s southeast.
Read More...
-
Chidamide gets approval in China for breast cancer indication
Drug development company Chipscreen Biosciences’ oral subtype-selective histone deacetylase (HDAC) inhibitor, Epidaza (Chidamide), has secured...
Read More...